Agreement with VGM, largest DSO in US-replacement

RNS Number : 6508U

Belluscura PLC

02 August 2022

 

The following amendment has been made to the announcement released at 07:00 on 2 August 2022 under RNS No. 5191U.

The heading of the notification has been corrected to identify the counterparty to the Supply Agreement as VGM. All other details remain unchanged.  The full corrected announcement is set out below.

Belluscura plc

("Belluscura" or the "Company")

Belluscura Signs Supply Agreement with the Largest Member Service Organisation (MSO) in the US

VGM & Associates MSO comprises over 2,500 providers with nearly 7,000 locations

Belluscura, a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that it has entered into a Group Purchasing Organization Product Supply Agreement (the "Agreement") for the supply of portable oxygen concentrators with VGM Group, Inc ("VGM"). 

VGM is the largest and most comprehensive Member Service Organization ("MSO") in the US for post-acute healthcare, which provides a range of support to its members including with the purchasing of medical equipment in the respiratory field.

Over 2,500 healthcare providers with nearly 7,000 locations across the US rely on VGM to connect them to valuable resources every single day.

VGM's providers will immediately gain access to Belluscura's award winning next generation portable oxygen concentrator, the X-PLOR®, which was launched in late June 2022, and later this year will gain access to Belluscura's transformational portable oxygen concentrator, the DISCOV-R™.

The Agreement with VGM further expands Belluscura's distribution network across the US and its routes to market.

Robert Rauker, CEO of Belluscura plc, said:

"Our partnership with VGM enables us to work together to provide access to our next generation portable oxygen concentrators. The partnership provides a further opportunity to support the Group's continued growth. We look forward to working with VGM in expanding access to our high performing, lighter oxygen technologies and improving the quality of life for patients."

ENDS

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

For further information, please contact:

Belluscura plc	www.belluscura.com
Robert Rauker, Chief Executive Officer	via MHP
Anthony Dyer, Chief Financial Officer
SPARK Advisory Partners Limited (NOMAD)	Tel: [phone]
Neil Baldwin
Dowgate Capital Limited (Broker)	Tel: [phone]
James Serjeant / Nicholas Chambers
MHP Communications (Financial PR and Investor Relations)	Tel: [phone]
Katie Hunt / Pete Lambie / Matthew Taylor	Email: [e-mail]

About Belluscura plc   (   www.belluscura.com   )

Belluscura is a UK medical device company focused on developing high performing, lightweight and portable oxygen enrichment technology used in a broad range of industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health, mobility and economic outcomes for patients, healthcare providers and insurance organisations.

Glossary

X-PLOR® is a lightweight portable oxygen concentrator with user replaceable oxygen enrichment cartridge and direct-charge batteries. Weighing only 3.75 lbs, its Airgonomic^TM Design ensures user-friendly experience and maximum comfort. It has multiple Pulse Flow Settings including X-PLORATION^TM Mode (750mL for 10 mins).

DISCOV-R™ will deliver 2000mL of continuous flow oxygen and have 8 Pulse Flow Settings. Weighing only 6.5 lbs, it will be the first a mbulatory 2L portable oxygen concentrator, producing more oxygen per pound than others in its class.

 

END

 

 

MSCSSFFFEEESEIA